These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33550238)

  • 21. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.
    Neffendorf JE; Desai R; Wang Y; Kelly J; Murphy C; Reeves BC; Chakravarthy U; Wordsworth S; Lewis C; Peacock J; Uddin S; O'Sullivan JM; Jackson TL
    Trials; 2016 Nov; 17(1):560. PubMed ID: 27881184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.
    Danyliv A; Glanville J; McCool R; Ferreira A; Skelly A; Jacob RP
    Adv Ther; 2017 Mar; 34(3):611-619. PubMed ID: 28188433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
    Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
    BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis.
    Samacá-Samacá D; Hernández-Castillo C; Prieto-Pinto L; Rodríguez F; Sardi C; Ocampo H; Kock J; Hernández F
    BMJ Open Ophthalmol; 2024 Jul; 9(1):. PubMed ID: 39043575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
    Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
    Campochiaro PA; Marcus DM; Awh CC; Regillo C; Adamis AP; Bantseev V; Chiang Y; Ehrlich JS; Erickson S; Hanley WD; Horvath J; Maass KF; Singh N; Tang F; Barteselli G
    Ophthalmology; 2019 Aug; 126(8):1141-1154. PubMed ID: 30946888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
    Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
    JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
    Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
    Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
    Waldstein SM; Wright J; Warburton J; Margaron P; Simader C; Schmidt-Erfurth U
    Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Fang HS; Bai CH; Cheng CK
    Retina; 2023 Mar; 43(3):420-432. PubMed ID: 36669130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis.
    Tricco AC; Thomas SM; Lillie E; Veroniki AA; Hamid JS; Pham B; Lee T; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Janoudi G; Muni RH; Francisconi CLM; Richter T; Straus SE
    Syst Rev; 2021 Dec; 10(1):315. PubMed ID: 34930439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
    Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
    Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration.
    Waldstein SM; Coulibaly L; Riedl S; Sadeghipour A; Gerendas BS; Schmidt-Erfurth UM
    Br J Ophthalmol; 2020 Jul; 104(7):899-903. PubMed ID: 31563866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.